Veil-Picard, Matthieu
Soumagne, Thibaud
Vongthilath, Rechana
Annesi-Maesano, Isabella
Guillien, Alicia
Laurent, Lucie
Andujar, Pascal
Roche, Nicolas
Jouneau, Stephane
Cypriani, Benoit
Laplante, Jean-Jacques
Degano, Bruno
Dalphin, Jean-Charles
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 1 April 2019
Accepted: 23 May 2019
First Online: 17 June 2019
Ethics approval and consent to participate
: Ethical approval was received from the local Ethics Committee (CPP Est; 11/617) and written consent was obtained from all subjects.
: Written consent was obtained from all subjects.
: Dr. Roche reports grants and personal fees from Boehringer Ingelheim, Pfizer and Novartis, personal fees from Teva, GSK, AstraZeneca, Chiesi, Mundipharma, Cipla, Sano, Sandoz, 3 M, Zambon, outside the submitted work. Dr. Dalphin reports grants, personal fees and non-financial support from Novartis Pharma, GSK, Chiesi, Intermune, AstraZeneca, Boehringer ingelheim and non-financial support from Stallergenes, outside the submitted work.Dr. Dalphin reports grants, personal fees and non-financial support from Novartis Pharma, personal fees and non-financial support from GSK, personal fees and non-financial support from Chiesi, personal fees and non-financial support from Intermune, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer ingelheim, non-financial support from Stallergenes, outside the submitted work.The other authors declare that they have no conflict of interest for the submitted work.